Germ cell tumor screening: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) (Created page with "According to the US preventive services task force, screening for ovarian cancer is not recommended in asymptomatic women.<ref name="GrossmanCurry2018">{{cite jour...") |
Hudakarman (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
Ovarian germ cell tumor: | |||
According to the US preventive services task force, [[screening]] for [[ovarian cancer]] is not recommended in [[asymptomatic]] women.<ref name="GrossmanCurry2018">{{cite journal|last1=Grossman|first1=David C.|last2=Curry|first2=Susan J.|last3=Owens|first3=Douglas K.|last4=Barry|first4=Michael J.|last5=Davidson|first5=Karina W.|last6=Doubeni|first6=Chyke A.|last7=Epling|first7=John W.|last8=Kemper|first8=Alex R.|last9=Krist|first9=Alex H.|last10=Kurth|first10=Ann E.|last11=Landefeld|first11=C. Seth|last12=Mangione|first12=Carol M.|last13=Phipps|first13=Maureen G.|last14=Silverstein|first14=Michael|last15=Simon|first15=Melissa A.|last16=Tseng|first16=Chien-Wen|title=Screening for Ovarian Cancer|journal=JAMA|volume=319|issue=6|year=2018|pages=588|issn=0098-7484|doi=10.1001/jama.2017.21926}}</ref> | According to the US preventive services task force, [[screening]] for [[ovarian cancer]] is not recommended in [[asymptomatic]] women.<ref name="GrossmanCurry2018">{{cite journal|last1=Grossman|first1=David C.|last2=Curry|first2=Susan J.|last3=Owens|first3=Douglas K.|last4=Barry|first4=Michael J.|last5=Davidson|first5=Karina W.|last6=Doubeni|first6=Chyke A.|last7=Epling|first7=John W.|last8=Kemper|first8=Alex R.|last9=Krist|first9=Alex H.|last10=Kurth|first10=Ann E.|last11=Landefeld|first11=C. Seth|last12=Mangione|first12=Carol M.|last13=Phipps|first13=Maureen G.|last14=Silverstein|first14=Michael|last15=Simon|first15=Melissa A.|last16=Tseng|first16=Chien-Wen|title=Screening for Ovarian Cancer|journal=JAMA|volume=319|issue=6|year=2018|pages=588|issn=0098-7484|doi=10.1001/jama.2017.21926}}</ref> | ||
Testicular germ cell tumor: | |||
According to the '''KIT'' [[Mutation|Mutations]] Are Common in [[Testicular]] Seminomas' study, [[Screening (medicine)|screening]] for seminoma by using the highly sensitive combination of denaturing [[High performance liquid chromatography|high performance liquid chromatography (HPLC)]] and direct [[sequencing]] observed:<ref name="pmid14695343">{{cite journal |vauthors=Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC |title=KIT mutations are common in testicular seminomas |journal=Am. J. Pathol. |volume=164 |issue=1 |pages=305–13 |date=January 2004 |pmid=14695343 |pmc=1602213 |doi=10.1016/S0002-9440(10)63120-3 |url=}}</ref> | |||
*[[Mutation|Mutations]] of KIT [[exon]] 17 | |||
*[[Mutation|Mutations]] of D816H | |||
*[[Mutation|Mutations]] of Y823D | |||
Revision as of 19:51, 21 August 2019
Ovarian germ cell tumor: According to the US preventive services task force, screening for ovarian cancer is not recommended in asymptomatic women.[1]
Testicular germ cell tumor: According to the 'KIT Mutations Are Common in Testicular Seminomas' study, screening for seminoma by using the highly sensitive combination of denaturing high performance liquid chromatography (HPLC) and direct sequencing observed:[2]
- ↑ Grossman, David C.; Curry, Susan J.; Owens, Douglas K.; Barry, Michael J.; Davidson, Karina W.; Doubeni, Chyke A.; Epling, John W.; Kemper, Alex R.; Krist, Alex H.; Kurth, Ann E.; Landefeld, C. Seth; Mangione, Carol M.; Phipps, Maureen G.; Silverstein, Michael; Simon, Melissa A.; Tseng, Chien-Wen (2018). "Screening for Ovarian Cancer". JAMA. 319 (6): 588. doi:10.1001/jama.2017.21926. ISSN 0098-7484.
- ↑ Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC (January 2004). "KIT mutations are common in testicular seminomas". Am. J. Pathol. 164 (1): 305–13. doi:10.1016/S0002-9440(10)63120-3. PMC 1602213. PMID 14695343.